Cost-effectiveness of FOLFIRI  + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.

Conclusions: Based on our analyses, FOLFIRI-cet is cost-effective compared with FOLFIRI-bev in patients with RAS wt mCRC, with ICERs well below willingness-to-pay thresholds for diseases with a high burden. PMID: 31903807 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research